铁调素与慢性肾脏病(透析与非透析)患者心血管事件的关系
本研究为ASCEND-ND和ASCEND-D两项3期试验的事后分析,分别纳入3807例非透析和2881例透析的贫血CKD患者,按基线铁调素四分位分组。非透析患者中基线铁调素与主要不良心血管事件(MACE)呈非线性关联(非线性P=0.032),透析患者中无关联;基线铁调素未改变达普司他相较于促红细胞生成剂(ESA)的治疗效应。
要点
- 非透析CKD贫血患者中,基线铁调素与MACE呈非线性关联,Q4风险最高。
- 透析CKD贫血患者中,基线铁调素四分位与MACE无关联。
- 基线铁调素未改变达普司他对比ESA的治疗效应,指导治疗选择价值有限。
核心结论
- 非透析CKD患者中基线铁调素与MACE呈非线性关联,透析患者中无关联。
- 无论透析状态如何,基线铁调素均未改变达普司他相较于ESA的治疗效应,提示其指导治疗选择的价值有限。
研究设计与样本
- ASCEND-ND和ASCEND-D两项3期试验的事后分析,分别纳入3807例非透析和2881例透析的贫血CKD患者。
- 按基线铁调素水平四分位(Q1-Q4)分组,比较MACE发生率及达普司他治疗效应。
主要发现
- ASCEND-ND和ASCEND-D中基线铁调素中位数分别为106 ng/ml和176 ng/ml。
- 两项试验中,较高基线铁调素与女性、较低血红蛋白、较高转铁蛋白饱和度、较高铁蛋白及较高C反应蛋白相关。
- 非透析患者中,MACE的Kaplan-Meier曲线显示Q2发生率最低,其次为Q1和Q3,Q4最高;风险因素校正后关联持续(非线性P=0.032)。
- 透析患者中,基线铁调素四分位与MACE无关联,校正混杂因素后仍一致。
- 铁调素的时间变化未独立 associated with MACE风险。
关键数值与推荐
- 非透析患者中基线铁调素与MACE非线性关联的P值为0.032(校正后)。
临床怎么用
- 在贫血CKD患者中,基线铁调素水平不宜用于指导达普司他或ESA的治疗选择。
- 非透析CKD患者中较高基线铁调素与较高MACE风险相关,但需进一步验证。
局限性
- 本研究为事后分析,结果需前瞻性研究验证。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hepcidin's prognostic role in patients with anemia and chronic kidney disease (CKD), regardless of dialysis requirement, remains unclear. METHODS: This was a post hoc analysis of Anemia Studies in CKD: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Nondialysis (ASCEND-ND) and Anemia Studies in CKD: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D), 2 phase 3 trials assessing daprodustat's efficacy and safety compared with conventional erythropoiesis-stimulating agents (ESAs). Patients were divided according to quartiles (Q1-4) of baseline hepcidin levels. RESULTS: In ASCEND-ND and ASCEND-D, baseline hepcidin values were available for 3807 and 2881 patients (medians: 106 ng/ml and 176 ng/ml), respectively. Higher baseline hepcidin levels were associated with female sex, lower hemoglobin levels, higher transferrin saturation, higher ferritin levels, and higher C-reactive protein levels in both trials. In nondialysis patients, Kaplan-Meier (KM) curves for major adverse cardiovascular events (MACE) demonstrated that Q2 exhibited the lowest incidence, followed by Q1 and Q3, with Q4 having the highest. This association persisted after risk factor adjustment (P for nonlinearity: 0.032). In dialysis patients, KM curves for MACE demonstrated no association between baseline hepcidin quartiles and MACE, remaining consistent following adjustment for confounding factors. Temporal changes in hepcidin levels were not independently associated with MACE risk. Daprodustat's treatment effects were not modified by baseline hepcidin levels in either trial. CONCLUSION: In nondialysis patients with CKD, a nonlinear relationship was observed between baseline hepcidin levels and MACE, whereas no association was found in dialysis patients. Baseline hepcidin levels did not modify the treatment effect of daprodustat compared with ESAs, irrespective of dialysis status, suggesting limited utility of hepcidin for guiding treatment selection.
引用
- Fujimoto Y, Matsue Y, Nakade T, et al. Hepcidin and Cardiovascular Events in CKD With and Without Dialysis. Kidney Int Rep. 2026. PMID: 42604012. doi:10.1016/j.ekir.2026.106703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。